Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MAIA
Strong SellSinkerMAIA Biotechnology, Inc. · Healthcare · United States · $81M · Avg Vol: $480K/d
11
StockRankGet insider-trade alerts
Q
25
V
27
M
34
P/E (TTM)
—
ROE
-218.7%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.32 | -0.42 | -0.45 | -0.70 | — | -0.63 | -0.54 | 1.11 | — |
| Shares | 60.8M | 60.8M | 60.8M | 38.6M | -36.5% | — | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 8.5M | 0.5M | 3.6M | 2.4M | -34.6% | — | — | — | — |
| Op CF | -12.1M | -13.1M | -15.7M | -18.8M | — | -22.6M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — |
| Fin CF | 12.5M | 9.3M | 18.2M | 17.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+4.8%
SMA 50SMA 200
Close
$1.31
RSI (14)
41.0
52W High
$3.19
From 52W High
0.4%
SCORE BREAKDOWN
Quality
25
ROIC
-631.7%0.7
ROE
-218.7%3.9
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-122.1%1.5
Piotroski
211.9
Int. Cover
—N/A
D/E Ratio
0.00x98.1
Current Ratio
4.51x69.0
Value
27
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
3.9x37.2
P/S
—N/A
Div Yield
—N/A
Momentum
34
52W High %
41%15.3
RS 6M
-29%29.5
SMA 50/200
0.92x35.2
EPS Rev 4W
-0.9%25.5
EPS Rev 12W
—N/A
EPS Improve
+276%91.1
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$81M
P/E (Forward)
1.2x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MAIA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MAIA | MAIA Biotechnology, Inc.(you) | $81M | 11 | Strong Sell |
| TENX | Tenax Therapeutics, Inc. | $80M | 12 | Strong Sell |
| ANVS | Annovis Bio, Inc. | $73M | 12 | Strong Sell |
| TELO | Telomir Pharmaceuticals, Inc. | $78M | 13 | Strong Sell |
| PLRX | Pliant Therapeutics, Inc. | $69M | 12 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
| OSTX | OS Therapies Incorporated | $76M | 15 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%